Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Terns Pharmaceuticals (TERN – Research Report) and TScan Therapeu...

Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and TScan Therapeutics (TCRX)

Barclays analyst Etzer Darout maintained a Buy rating on Terns Pharmaceuticals today and set a price target of $36.00. Darout covers the Healthcare...

Barclays Remains a Buy on Terns Pharmaceuticals (TERN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Terns Pharmaceuticals (TERN – Research Report) and...

Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN) and Ironwood Pharma (IRWD)

In a report released yesterday, Etzer Darout from Barclays maintained a Buy rating on Terns Pharmaceuticals, with a price target of $36.00. The com...

Market Cap	$1.62B	P/E Ratio	N/A
52W High	$30.25	52W Low	$1.87
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	20.3%	52W Position	152.0%
Overall Score	64	Value Score	50
Quality Score	52	Technical Score	91

EPS Current Est	$-1.08	EPS Next Est	$-1.31
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TERN	$45.00	-4.44%	6.88M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TERN	$45.00	-4.4%	6.88M
3
4
5
6

TERN

TERN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Terns Pharmaceuticals Inc. Data in Excel

Get Terns Pharmaceuticals Inc. Data in Excel